Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 11, 2025
Deals
After stumbles along winding path, Acelyrin merges with Alumis: Deals Report
Plus: Pair of cash-rich biotechs agree to combine, and Australian radiopharma company Advancell follows venture round by expanding Lilly relationship
BioCentury | Dec 4, 2024
Product Development
Confidence in masked T cell engagers builds with Janux update
Also in BioCentury’s Clinical Report: Cartesian’s autoimmune CAR T durability, Roivant’s miss, Novocure’s pancreatic cancer data, and more
BioCentury | Nov 20, 2024
Discovery & Translation
Science Spotlight: A new obesity target may avoid nausea, muscle loss
BioCentury’s roundup of translational innovation: Embark/Novo discover new obesity target, Canbridge delivers large DMD gene, and more
BioCentury | Nov 20, 2024
Deals
Where the Ratio deal fits into Novartis’ radiopharma matrix
The deal grows Novartis’ ligand modality and chelator toolbox, and its focus on Lutathera target SSTR2
BioCentury | May 28, 2024
Deals
J&J adds bispecific for atopic dermatitis via deal with Numab
Ten-figure M&A transaction with Swiss antibody company gives the pharma an immunology asset targeting IL-4RA and IL-31; builds on Proteologix deal
BioCentury | May 17, 2024
Product Development
Vectorized antibodies are taking gene therapy beyond rare disease
ASGCT presentations showcase cancers, infectious diseases and chronic inflammatory conditions as potential applications of vectorized antibodies
BioCentury | Apr 24, 2024
Product Development
Next-wave radiopharmaceuticals: insights from AACR
Fusion added to view of ɑ-emitters in lutetium-experienced patients, as Novartis, RayzeBio gave peeks at programs with broad indication potential
BioCentury | Mar 26, 2024
Distillery Therapeutics
Increasing podocyte NDUFS4 for diabetic kidney disease
BioCentury | Jan 26, 2024
Product Development
Growing IL-18 field looks to enhance cell therapies via decoy evasion
As more companies bring IL-18 into their cancer pipelines, they also bring new modalities and approaches to the cytokine’s inhibitory decoy receptor
Items per page:
1 - 10 of 826